Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).
| Revenue (Most Recent Fiscal Year) | $332.31M |
| Net Income (Most Recent Fiscal Year) | $-51.74M |
| PE Ratio (Current Year Earnings Estimate) | 506.00 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 136.39 |
| Price to Sales Ratio (Trailing 12 Months) | 1.90 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 105.30 |
| Pre-Tax Margin (Trailing 12 Months) | -38.80% |
| Net Margin (Trailing 12 Months) | -35.84% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -28.41% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.15 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.76 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.06 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.97 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.02 |
| Earnings per Share (Most Recent Fiscal Year) | $0.01 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.49 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 201.62M |
| Free Float | 198.19M |
| Market Capitalization | $510.11M |
| Average Volume (Last 20 Days) | 8.60M |
| Beta (Past 60 Months) | 0.96 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 47.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |